Drugs / RP72
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04338763 | Apr 2021 → Oct 2024 | malignant pancreatic neoplasm | Rise Biopharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP72 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04338763 ↗ |
| Action | Inhibit | “RP72 can inhibit the binding of CXCL8 to its receptors CXCR1/2” NCT04338763 ↗ |
| Modality | Protein / enzyme biologic | “RP72 (Rise Prot-72) is a small molecular weight protein” NCT04338763 ↗ |
| Route | Intravenous | “IV injection of RP72 will be administered” NCT04338763 ↗ |
| Target | CXCR1 | “RP72 (Rise Prot-72) is a small molecular weight protein which directly binds to CXCR1 and CXCR2” NCT04338763 ↗ |
| Target | CXCR2 | “RP72 (Rise Prot-72) is a small molecular weight protein which directly binds to CXCR1 and CXCR2” NCT04338763 ↗ |